The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy (ESMGC)
Phase II Randomized Controlled Trial Evaluating the Necessity of Surgery in Patients With Advanced Metastatic Gastric Cancer Achieving Radiological Response After Conversion Therapy
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The innovation and scientific nature of this study lie in its adoption of a multi-center, randomized controlled Phase II study design for the first time. It directly compares the efficacy differences between "surgery + postoperative adjuvant therapy" and "simple continuation of medical treatment" for this specific population, aiming to eliminate selection bias and confirm the causal relationship. We strictly limited the enrolled population to those with "significant imaging remission and technically resectable at R0 level" by MDT assessment, ensuring the homogeneity of the research subjects and the specificity of the questions. The primary research endpoint was set as progression-free survival (PFS), and secondary endpoints included overall survival (OS), R0 resection rate, quality of life (QoL), and treatment-related toxic side effects, allowing for a comprehensive evaluation.
Carrying out this study has significant scientific and clinical value. Its results will provide Level 1 evidence-based medical evidence for the treatment strategy of this population. If the surgical group shows superiority, it will firmly establish the position of surgery and promote it to become the standard treatment; if the results are negative (equivalence between the two groups or the surgical group is inferior), it will avoid a large number of patients suffering from unnecessary surgical trauma, promoting the treatment model to return to a core of systematic treatment, thereby changing global clinical guidelines. At the same time, the study has important health economics significance, helping to allocate limited medical resources to truly benefit patients. Through exploratory research on biological specimens, it can also deepen the understanding of the biological behavior of advanced gastric cancer and provide clues for more precise patient screening in the future.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Xu Dazhi Director of Gastric Surgery Department, Doctoral candidate
- 電話番号:+8618121299796
- メール:xudzh@shca.org.cn
研究連絡先のバックアップ
- 名前:Yang Han, Doctoral candidate
- 電話番号:+8618121299599
- メール:hanyang0811@163.com
研究場所
-
-
-
Shanghai、中国、200032
- 募集
- Fudan University Cancer Hospital
-
コンタクト:
- Weijing Zhang
- 電話番号:+86 21 3477 8299
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age and Informed Consent: The age range is 18 to 75 years (inclusive), and the participant must voluntarily participate in this study and sign the patient informed consent approved by the ethics committee.
- Pathological Diagnosis: Gastric or gastroesophageal junction (GEJ) adenocarcinoma confirmed by histological or cytological examination.
- Disease Staging: Newly diagnosed, unresectable stage IV disease (according to the 8th edition of the AJCC staging system), confirmed by the multidisciplinary team (MDT) of the research center to be unable to undergo radical surgical resection. The types of metastasis include but are not limited to: unresectable distant lymph node metastasis (such as beyond the abdominal aorta trunk, supraclavicular lymph nodes, etc.); distant organ metastasis (such as liver, lungs, peritoneum, ovaries, etc.).
Conversion Therapy and Efficacy:
- Has received 4-6 cycles of first-line standard conversion therapy. The treatment plan should be based on the latest clinical guidelines and molecular typing (such as fluorouracil/platinum double or triple drug chemotherapy, combined with anti-HER2 treatment (for HER2-positive patients) or immune checkpoint inhibitors (PD-1/PD-L1 inhibitors, such as when CPS ≥ 5 or MSI-H, etc.).
- After conversion therapy, according to the RECIST 1.1 standard, confirmed by the independent imaging assessment committee (IRC) or at least two senior radiologists, the efficacy reaches complete response (CR) or partial response (PR).
- Surgical Feasibility Assessment: Re-evaluated by the MDT of the research center (must include senior gastrointestinal surgeons, oncologists, and radiologists), it is considered that all known lesions (primary and metastatic lesions) can be technically achieved R0 resection, and the patient is expected to be safely and tolerably able to undergo surgery.
- Physical Condition: Eastern Cooperative Oncology Group (ECOG) performance status score (PS) of 0 or 1.
Good Organ Function (measured within 14 days before randomization), meeting the following laboratory test value standards:
Hematological System:
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L Platelet count (PLT) ≥ 100 × 10⁹/L Hemoglobin (Hb) ≥ 90 g/L
Liver Function:
Serum total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (if liver metastasis, then ≤ 5 × ULN)
- Renal Function:
Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate (Ccr) ≥ 50 mL/min (Cockcroft-Gault formula)
- Female patients of childbearing age must have a negative serum pregnancy test within 7 days before randomization, and all patients (regardless of gender) must agree to take effective contraceptive measures during the study and within 6 months after treatment.
Exclusion Criteria:
- Pathological type: Other pathological types, such as squamous cell carcinoma, adenosquamous carcinoma, undifferentiated carcinoma, gastrointestinal stromal tumor (GIST), etc.
Treatment and efficacy:
- During the conversion therapy, disease progression (PD) was confirmed after assessment.
- Previously received systemic anti-tumor treatment for advanced gastric cancer (except for conversion therapy).
- Previously received radical radiotherapy for the stomach or metastatic lesions.
Surgical contraindications:
- According to MDT assessment, there are residual lesions that cannot be surgically removed (such as diffuse peritoneal metastasis that cannot achieve satisfactory tumor reduction, extensive liver metastasis that cannot preserve sufficient functional liver tissue, etc.).
- There are severe internal medical comorbidities that significantly affect surgical safety, and the anesthesiology and surgical physicians have evaluated that the surgical risk is extremely high, for example:
Uncontrolled heart failure (NYHA cardiac function class III-IV), unstable angina or myocardial infarction within 6 months.
Severe chronic obstructive pulmonary disease (COPD) or other severe respiratory diseases, which are expected to be intolerant to general anesthesia.
Uncontrollable severe infection.
Past and coexisting disease history:
- In the past 5 years, had other active malignant tumors, except for cured skin basal cell carcinoma, cervical carcinoma in situ, etc.
- Had any uncontrolled severe clinical problems (such as severe mental or neurological diseases) that affected the compliance with the protocol or interfered with the interpretation of the research results.
- Laboratory test abnormalities: Any serious and uncontrolled laboratory test abnormalities were found. The investigator considered that participating in this study would bring significant risks.
- Pregnancy and lactation: Pregnant or lactating women.
- Other: Known to have a severe allergic history to any drugs (chemotherapy drugs, targeted drugs, immunotherapies, anesthetics, etc.) used in the study protocol. The investigator believed that there were any other situations that were not suitable for participating in this clinical study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:The surgical group
Surgical radical resection (primary lesion + metastatic lesion) + postoperative adjuvant therapy
|
Surgical radical resection (primary lesion + metastatic lesion)
|
|
実験的:The non-surgical group
Without surgery, continue with the original medical treatment plan until the disease progresses or intolerable toxicity occurs.
|
Without surgery, continue with the original medical treatment plan until the disease progresses or intolerable toxicity occurs.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
2-year PFS
時間枠:2 year
|
Two-year progression-free survival rate
|
2 year
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
2-year OS
時間枠:2 year
|
2 year Overall Survival
|
2 year
|
|
The R0 resection rate
時間枠:2 year
|
The R0 resection rate of surgery group
|
2 year
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
- Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020 Aug 29;396(10251):635-648. doi: 10.1016/S0140-6736(20)31288-5.
- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- ESMGC
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。